Call centre software producer Replicant closed a $78m series B round backed by Salesforce Ventures while Ashvattha Therapeutics raised $69m from investors including strategic partner Huadong Medicine.

Funding Replicant, a US-based provider of contact centre automation software, completed a $78m series B round on Tuesday featuring Salesforce Ventures, the corporate venture capital arm of enterprise software producer Salesforce. Growth equity firm Stripes led the round, which included IronGrey, Omega Venture Partners, Norwest Venture Partners and Replicant’s founding investor, venture studio Atomic. Pharmaceutical…

The rest of this content is only accessible to Global Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.